fluvoxamine has been researched along with Colitis* in 1 studies
1 other study(ies) available for fluvoxamine and Colitis
| Article | Year |
|---|---|
Lessons on the Sigma-1 Receptor in TNBS-Induced Rat Colitis: Modulation of the UCHL-1, IL-6 Pathway.
Inflammatory Bowel Disease (IBD) is an autoimmune ailment of the gastrointestinal (GI) tract, which is characterized by enhanced activation of proinflammatory cytokines. It is suggested that the sigma-1 receptor (σ1R) confers anti-inflammatory effects. As the exact pathogenesis of IBD is still unknown and treatment options are limited, we aimed to investigate the effects of σ1R in 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced experimental colitis. To this end, male Wistar-Harlan rats were used to model colitic inflammation through the administration of TNBS. To investigate the effects of σ1R, Fluvoxamine (FLV, σ1R agonist) and BD1063 (σ1R antagonist) were applied via intracolonic administration to the animals once a day for three days. Our radioligand binding studies indicated the existence of σ1Rs as [ Topics: Animals; Colitis; Cytokines; Disease Models, Animal; Disease Susceptibility; Fluvoxamine; Gene Expression Regulation; Heme Oxygenase (Decyclizing); Inflammation Mediators; Interleukin-6; Ligands; NF-kappa B; Nitric Oxide Synthase Type II; Peroxidase; Protein Binding; Rats; Receptors, sigma; Severity of Illness Index; Sigma-1 Receptor; Signal Transduction; Trinitrobenzenesulfonic Acid; Ubiquitin Thiolesterase | 2020 |